Recently, potent anti-viral and anti-tumor responses related to enhanced CD8+ T cell effector activity were generated following synergistic dual blockade of PD-L1 and TIGIT in the mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection [18] and ex-vivo in patients with advanced melanoma [19]. The gene discussed is TIGIT; the disease is melanoma.